These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23775007)

  • 21. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease.
    Hsieh CJ; Wang PW
    Circ J; 2009 May; 73(5):948-54. PubMed ID: 19282610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
    Rossing P; Block GA; Chin MP; Goldsberry A; Heerspink HJL; McCullough PA; Meyer CJ; Packham D; Pergola PE; Spinowitz B; Sprague SM; Warnock DG; Chertow GM
    Kidney Int; 2019 Oct; 96(4):1030-1036. PubMed ID: 31377056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial.
    Hadjadj S; Gourdy P; Zaoui P; Guerci B; Roudaut N; Gautier JF; Chabin M; Mauco G; Ragot S;
    Diabet Med; 2007 Aug; 24(8):906-10. PubMed ID: 17451421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cilostazol in treating diabetes-associated microvascular complications.
    Asal NJ; Wojciak KA
    Endocrine; 2017 May; 56(2):240-244. PubMed ID: 28293857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects.
    Kim JH; Hong KW; Bae SS; Shin YI; Choi BT; Shin HK
    Int J Mol Med; 2014 Sep; 34(3):687-94. PubMed ID: 25017431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cilostazol Can Increase Skin Oxygen Supply Assessed by Transcutaneous Oxygen Pressure Measurement in Type 2 Diabetes With Lower Limb Ischemic Disease: A Randomized Trial.
    Zhang J; Xiao Z; Chen L; Li L; Yang H; Luo B; Mai L; Yan L; Yang C
    J Wound Ostomy Continence Nurs; 2016; 43(3):254-9. PubMed ID: 26938333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.
    Heerspink HL; Greene T; Lewis JB; Raz I; Rohde RD; Hunsicker LG; Schwartz SL; Aronoff S; Katz MA; Eisner GM; Mersey JH; Wiegmann TB;
    Nephrol Dial Transplant; 2008 Jun; 23(6):1946-54. PubMed ID: 18089623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
    Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
    Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril.
    Ko GT; Tsang CC; Chan HC
    Adv Ther; 2005; 22(2):155-62. PubMed ID: 16020405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.
    Ravid M; Brosh D; Levi Z; Bar-Dayan Y; Ravid D; Rachmani R
    Ann Intern Med; 1998 Jun; 128(12 Pt 1):982-8. PubMed ID: 9625684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Justifying the high prevalence of microalbuminuria for type 2 diabetic patients in Taiwan with conditional probability approach--a DEMAND II study.
    Chiang SC; Lee JK; Chen CH; Chuang LM; Tsan KW; Sheu WH; Wu DA; Wu TJ; Lin KC; Juang JH; Wang CY; Ho LT
    J Chin Med Assoc; 2011 Jan; 74(1):3-10. PubMed ID: 21292196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.